ofatumumab
FDA extends review of Novartis’ MS drug ofatumumab
Richard Staines
fda, multiple sclerosis, Novartis, ofatumumab, R&D, Roche
0 Comment
X
FDA extends review of Novartis’ MS drug ofatumumab
https://pharmaphorum.com/news/fda-extends-review-of-novartis-ms-drug-ofatumumab/